Please wait while the formulary information is being retrieved.
Drug overview for AFRIN (oxymetazoline hcl):
Generic name: OXYMETAZOLINE HCL
Drug class: Nasal Decongestants
Therapeutic class: Respiratory Therapy Agents
Oxymetazoline hydrochloride, an imidazoline-derivative sympathomimetic amine, is a vasoconstrictor.
No enhanced Uses information available for this drug.
Generic name: OXYMETAZOLINE HCL
Drug class: Nasal Decongestants
Therapeutic class: Respiratory Therapy Agents
Oxymetazoline hydrochloride, an imidazoline-derivative sympathomimetic amine, is a vasoconstrictor.
No enhanced Uses information available for this drug.
DRUG IMAGES
AFRIN ORIGINAL 0.05% PUMP MIST
AFRIN 0.05% NASAL SPRAY
The following indications for AFRIN (oxymetazoline hcl) have been approved by the FDA:
Indications:
Nasal congestion
Professional Synonyms:
Nasal stuffiness
Indications:
Nasal congestion
Professional Synonyms:
Nasal stuffiness
The following dosing information is available for AFRIN (oxymetazoline hcl):
No enhanced Dosing information available for this drug.
Oxymetazoline hydrochloride nasal solutions are applied topically to the nasal mucosa as sprays. Oxymetazoline hydrochloride nasal solutions also are administered by a nasal pump that produces metered sprays. Ophthalmic solutions of the drug are applied topically to the conjunctiva.
Care must be taken to avoid contamination of the dropper, inhaler, or spray dispenser. It is recommended that contact lenses be removed before topical administration of the ophthalmic solution. Sprays (including metered sprays) should be delivered or pumped into each nostril with the patient's head erect so that excess solution is not released.
Prior to initial use of metered sprays, the nasal inhalers should be primed by depressing the pump firmly several times. To minimize the risk of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, or droppers should be rinsed with hot water or wiped clean following use.
Care must be taken to avoid contamination of the dropper, inhaler, or spray dispenser. It is recommended that contact lenses be removed before topical administration of the ophthalmic solution. Sprays (including metered sprays) should be delivered or pumped into each nostril with the patient's head erect so that excess solution is not released.
Prior to initial use of metered sprays, the nasal inhalers should be primed by depressing the pump firmly several times. To minimize the risk of spreading infections, droppers, inhalers, and spray dispensers should not be used by more than one person, and tips of the dispensers, inhalers, or droppers should be rinsed with hot water or wiped clean following use.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| AFRIN 0.05% NASAL SPRAY | Maintenance | Adults spray 2 sprays in each nostril by intranasal route 2 times per day in the morning and evening |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PUB OXYMETAZOLINE HCL 0.05% | Maintenance | Adults spray 2 sprays in each nostril by intranasal route 2 times per day inthe morning and evening |
| OXYMETAZOLINE 0.05% SPRAY | Maintenance | Adults spray 2 sprays in each nostril by intranasal route 2 times per day inthe morning and evening |
The following drug interaction information is available for AFRIN (oxymetazoline hcl):
There are 0 contraindications.
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Zavegepant/Intranasal Decongestants SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Intranasal decongestants may decrease the absorption of zavegepant.(1) CLINICAL EFFECTS: Concurrent administration of intranasal decongestants may result in decreased systemic exposure and effectiveness of zavegepant.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent use of intranasal decongestants with zavegepant. If concurrent use is unavoidable, use the decongestant at least 1 hour after zavegepant.(1) DISCUSSION: Intranasal decongestants may lower absorption of zavegepant. This effect has not been clinically evaluated.(1) |
ZAVZPRET |
The following contraindication information is available for AFRIN (oxymetazoline hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Angle-closure glaucoma |
| Benign prostatic hyperplasia |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Atherosclerotic cardiovascular disease |
| Coronary artery disease |
| Diabetes mellitus |
| Hypertension |
| Hyperthyroidism |
The following adverse reaction information is available for AFRIN (oxymetazoline hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 8 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dizziness Headache disorder Insomnia Nervousness Rebound nasal congestion Tremor |
| Rare/Very Rare |
|---|
|
Cardiac arrhythmia Hypertension |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dry nose Nasal passage irritation Rhinorrhea Sneezing |
| Rare/Very Rare |
|---|
|
Nausea Palpitations |
The following precautions are available for AFRIN (oxymetazoline hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Safe use of oxymetazoline during pregnancy has not been established. Oxymetazoline hydrochloride ophthalmic or nasal solutions should be used during pregnancy only when instructed by a clinician.
It is not known whether oxymetazoline is distributed into milk. Topical oxymetazoline preparations should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for AFRIN (oxymetazoline hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for AFRIN (oxymetazoline hcl)'s list of indications:
| Nasal congestion | |
| R09.81 | Nasal congestion |
Formulary Reference Tool